Gynecologic Cancer
EC145 in Combination With Doxil® for Platinum Resistant Ovarian Cancer (7334)
Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer
Investigator: Barbara Ann Goff, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01170650
A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Investigator: Benjamin Greer, MD; Conditions: Gynecological Cancer; Ovarian Cancer; Solid Tumors; Uterine Cancer; Status: Recruiting; Study ID: NCT00954174
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Investigator: Benjamin Greer, MD; Conditions: Cervical Cancer; Status: Recruiting; Study ID: NCT00980954
A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT00942357
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
Investigator: Benjamin E. Greer, MD; Conditions: Endometrial Cancer, Fatigue, Neurotoxicity; Status: Recruiting; Study ID: NCT00807768
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Investigator: Benjamin E. Greer, MD; Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: NCT00565851
FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer
Investigator: Dr. Joseph Rajendran; Conditions: Advanced Ovarian Cancer; Status: Recruiting
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Investigator: Benjamin Greer, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01196429
Join Us On